title: Fludrocortisone for the treatment of heparin-induced hyperkalemia.
abstract: OBJECTIVE
  To report the use of fludrocortisone for heparin-induced hyperkalemia and to briefly review the available literature relating to heparin-induced hyperkalemia.
  
  
  METHODS
  A 34-year-old African-American man was admitted to the hospital for pneumococcal pneumonia and sepsis. His hospital course was complicated by the development of acute respiratory distress syndrome, severe sepsis, acute renal failure, placement of a tracheostomy, and recurrent nasopharyngeal bleeding. The patient also developed a subclavian vein thrombosis with extension to the cephalic and basilic veins secondary to placement of a pulmonary artery catheter; anticoagulation with heparin was required. On day 9 of heparin therapy, the patient developed symptomatic hyperkalemia refractory to conventional therapies. Oral fludrocortisone 0.1 mg/d was initiated with resolution of the hyperkalemia within 24 hours despite the continued administration of heparin.
  
  
  METHODS
  A MEDLINE (1966-October 1999) search was performed to identify case reports and clinical trials discussing heparin-induced hyperkalemia or the use of fludrocortisone for hyperkalemia.
  
  
  CONCLUSIONS
  Heparin has the potential to induce hyperkalemia by several mechanisms, including decreased aldosterone synthesis, reduction in number and affinity of aldosterone II receptors, and atrophy of the renal zona glomerulosa. Fludrocortisone promotes potassium excretion by its direct actions on the renal distal tubules. In this patient, fludrocortisone resulted in a significant and rapid decrease in serum potassium even with continued heparin administration and acute renal failure.
  
  
  CONCLUSIONS
  This case suggests that fludrocortisone is a reasonable alternative therapy for patients with hyperkalemia secondary to heparin therapy when the continued administration of heparin is necessary.
authors.affiliation: Department of Pharmacy Practice, School of Pharmacy, University of Colorado Health Sciences Center, Denver, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Sherman
authors.forename: C L
authors.initials: CL
authors.lastname: Kass
authors.forename: D N
authors.initials: DN
authors.lastname: Fish
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000378:metabolism; D000925:Anticoagulants / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004338:Drug Combinations; D005438:Fludrocortisone / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008901:Mineralocorticoids / Q000627:therapeutic use*; D011018:Pneumonia, Pneumococcal / Q000150:complications; D011188:Potassium / Q000097:blood; D012128:Respiratory Distress Syndrome / Q000150:complications; D012307:Risk Factors; D018805:Sepsis / Q000150:complications; D020246:Venous Thrombosis / Q000188:drug therapy
chemical_list: D000925:Anticoagulants; D004338:Drug Combinations; D008901:Mineralocorticoids; D000450:Aldosterone; D006493:Heparin; D003404:Creatinine; D011188:Potassium; D005438:Fludrocortisone